$XNCR

Feigal Ellen sold $89K of XNCR

Feigal Ellen sold 6,843 shares of Xencor Inc (XNCR) at $13.06 on 2026-06-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Feigal Ellen
Published Jun 22, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$XNCR
Neutral
medium confidence
Mentioned
$XNCR
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XNCRNeutralLow
01

Why it matters

The disclosed sale is a new, primary-source datapoint but is likely low-impact because it is pre-arranged under Rule 10b5-1 and lacks accompanying company-specific news.

02

Market read

Traders may briefly reassess sentiment around insider activity, but the 10b5-1 structure reduces the likelihood of a durable fundamental repricing.

03

What to watch

The filing does not state whether additional sales are planned, nor does it provide context on total insider holdings beyond the post-transaction figure; without that, signal quality is limited.

Relevance 2/10Novelty 4/10Timing: after-hours/filing time (2026-06-22) for an insider sale disclosed on SEC EDGAR

Background

The article is an SEC Form 4 insider transaction disclosure for Xencor Inc, reported by director Feigal Ellen.

Company-level read

Ticker impact

$XNCRNeutralMedium confidence
Context

SEC Form 4 shows director Feigal Ellen sold 6,843 shares of Xencor at $13.0600 on 2026-06-18 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a disclosed insider transaction with a pre-arranged 10b5-1 plan, and the article contains no new operational, financial, or regulatory developments.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations; traders may ignore it unless paired with other negative catalysts.

Key entities

  • Xencor Inc

    Subject of the Form 4 insider transaction; director Feigal Ellen sold shares under a 10b5-1 plan.

  • Feigal Ellen

    Director who sold 6,843 shares at $13.0600 on 2026-06-18; holdings after sale: 12,340 shares.

Related articles

$XNCRMed

Xencor Inc (XNCR): Results of Operations and Financial Condition

Xencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 xncr-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Xencor Reports Second Quarter 2026 Financial Results -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indica

$CORTMed

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

$XNCRMedAI 8/10

Xencor, Inc.: Xencor to Receive $105 Million From Alexion to Resolve Ultomiris U.S. Royalty Matter

Xencor (NASDAQ:XNCR) said it reached a settlement with Alexion to resolve a U.S. Ultomiris (ravulizumab-cwvz) royalty dispute. Under the agreement, Xencor will receive $105 million in two $52.5 million payments, expected in Aug. 2026 and one year later. Alexion will owe no further U.S. royalties, while ex-U.S. royalties continue. Xencor expects cash through 2028.

$XNCRMed

Xencor Inc (XNCR): Results of Operations and Financial Condition

Xencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. xncr-20260729 FALSE 0001326732 0001326732 2026-07-29 2026-07-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________________ FORM 8-K ___________________________________________________ CURRENT REPORT Pursuant to Sect